Abstract: Provided herein is a coated particle comprising: (i) a microparticle that comprises a pharmaceutically acceptable excipient and (ii) nanoparticles of a therapeutic agent, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein is a pharmaceutical composition comprising the coated particle. Furthermore, provided herein are methods of their preparation.
Type:
Application
Filed:
May 24, 2023
Publication date:
October 5, 2023
Applicant:
Nano PharmaSolutions, Inc.
Inventors:
Kay Olmstead, Saeyeon Lee, Seok-Keun Koh
Abstract: Provided herein is a coated particle comprising: (i) a microparticle that comprises a pharmaceutically acceptable excipient and (ii) nanoparticles of a therapeutic agent, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein is a pharmaceutical composition comprising the coated particle. Furthermore, provided herein are methods of their preparation.
Type:
Application
Filed:
February 18, 2021
Publication date:
September 23, 2021
Applicant:
Nano PharmaSolutions, Inc.
Inventors:
Kay Olmstead, Saeyeon Lee, Seok-Keun Koh
Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of Cyclosporin, in association with a pharmaceutical carrier, said carrier comprising a cyclosporin solubilizing effective amount of a propylene glycol monoester of C6-C18 fatty acid having at least 60% by weight monoester based on the total weight of the propylene glycol ester and a non-ionic surfactant.
Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of a lipophilic drug, in association with a pharmaceutical carrier, said carrier comprising a lipophilic drug solubilizing effective amount of a propylene glycol monoester of C6-C18 fatty acid having at least 60% by weight monoester based on the total weight of the propylene glycol ester and a non-ionic surfactant.
Abstract: The present invent is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of cyclosporin in association with a pharmaceutical carrier, said carrier comprising a drug solubilizing effective amount of a fatty acid having 6-22 carbon atoms and a non-ionic surfactant.